Roberts Glore & Co. Inc. IL Has $724,000 Position in St. Jude Medical Inc. (STJ)
Roberts Glore & Co. Inc. IL cut its stake in shares of St. Jude Medical Inc. (NYSE:STJ) by 1.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,279 shares of the medical technology company’s stock after selling 126 shares during the period. Roberts Glore & Co. Inc. IL’s holdings in St. Jude Medical were worth $724,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in the stock. Sphinx Trading LP acquired a new stake in St. Jude Medical during the second quarter valued at approximately $107,000. Checchi Capital Advisers LLC increased its stake in St. Jude Medical by 2.8% in the second quarter. Checchi Capital Advisers LLC now owns 2,332 shares of the medical technology company’s stock valued at $182,000 after buying an additional 64 shares during the period. IFP Advisors Inc increased its stake in St. Jude Medical by 14.8% in the first quarter. IFP Advisors Inc now owns 2,555 shares of the medical technology company’s stock valued at $141,000 after buying an additional 330 shares during the period. QUANTRES ASSET MANAGEMENT Ltd acquired a new stake in St. Jude Medical during the second quarter valued at approximately $203,000. Finally, Capital Investment Advisors LLC acquired a new stake in St. Jude Medical during the second quarter valued at approximately $211,000. 81.59% of the stock is currently owned by institutional investors and hedge funds.
St. Jude Medical Inc. (NYSE:STJ) traded down 0.23% during mid-day trading on Friday, reaching $77.98. 1,422,461 shares of the company’s stock were exchanged. The company’s 50 day moving average price is $79.09 and its 200-day moving average price is $75.66. St. Jude Medical Inc. has a 52 week low of $48.83 and a 52 week high of $84.00. The company has a market capitalization of $22.22 billion, a P/E ratio of 33.90 and a beta of 1.16.
St. Jude Medical (NYSE:STJ) last posted its earnings results on Wednesday, July 20th. The medical technology company reported $1.06 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $1.06. The firm earned $1.56 billion during the quarter, compared to the consensus estimate of $1.55 billion. St. Jude Medical had a net margin of 11.40% and a return on equity of 27.60%. The company’s revenue was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.07 EPS. On average, equities research analysts expect that St. Jude Medical Inc. will post $4.06 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 28th. Investors of record on Friday, September 30th will be given a dividend of $0.31 per share. This represents a $1.24 dividend on an annualized basis and a yield of 1.59%. The ex-dividend date is Wednesday, September 28th. St. Jude Medical’s dividend payout ratio (DPR) is presently 53.91%.
STJ has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of St. Jude Medical from a “hold” rating to a “buy” rating and set a $86.00 price target on the stock in a report on Tuesday, June 21st. Leerink Swann downgraded shares of St. Jude Medical from an “outperform” rating to a “market perform” rating in a report on Monday, July 11th. Wedbush downgraded shares of St. Jude Medical from an “outperform” rating to a “neutral” rating and increased their price target for the stock from $70.00 to $84.00 in a report on Friday, July 15th. JPMorgan Chase & Co. reissued a “hold” rating on shares of St. Jude Medical in a report on Sunday, July 17th. Finally, Barclays PLC increased their price target on shares of St. Jude Medical from $80.00 to $83.00 and gave the stock an “equal weight” rating in a report on Thursday, July 21st. Twenty-one equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $75.28.
About St. Jude Medical
St. Jude Medical, Inc is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders.
Want to see what other hedge funds are holding STJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for St. Jude Medical Inc. (NYSE:STJ).
Receive News & Ratings for St. Jude Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for St. Jude Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.